Tyra Biosciences, Inc. (TYRA)

17,20 -0,55 (-3,10%) Al cierre: 04:00PM EDT

Tyra Biosciences, Inc.

2656 State Street
Carlsbad, CA 92008
United States
619 728 4760
https://tyra.bio

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 49

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Todd Harris Ph.D.	Co-Founder, President, CEO, Secretary, Treasurer & Director	1,07M	N/A	1979
Mr. Alan Fuhrman	Chief Financial Officer	763,09k	N/A	1957
Dr. Hiroomi Tada M.D., Ph.D.	Chief Medical Officer	816,31k	N/A	1964
Mr. Daniel Bensen	Co-Founder & COO	630,8k	N/A	1976
Dr. Robert L. Hudkins Ph.D.	Chief Technology Officer	N/A	N/A	1956
Dr. Ronald V. Swanson Ph.D.	Chief Scientific Officer	536,19k	N/A	1964
Mr. Ali D. Fawaz J.D.	General Counsel	629,23k	N/A	N/A
Ms. Sarah Honig	Vice President of Corporate Development & Strategy	N/A	N/A	N/A
Dr. Piyush R. Patel Ph.D.	Chief Development Officer	N/A	N/A	1966
Amy Conrad	Investor Contact	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Gobierno corporativo

El ISS Governance QualityScore de Tyra Biosciences, Inc., a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 5; Derechos de los accionistas: 9; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.